{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:11:17Z","timestamp":1789931477860,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.bbrc.2017.01.031","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T08:31:13Z","timestamp":1483950673000},"page":"897-903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival"],"prefix":"10.1016","volume":"483","author":[{"given":"Yonghuai","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liusong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2017.01.031_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.critrevonc.2003.11.002","article-title":"Adult acute myeloid leukaemia","volume":"50","author":"Smith","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbrc.2017.01.031_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2017.01.031_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmet.2016.05.009","article-title":"The mechanistic target of rapamycin: the grand ConducTOR of metabolism and aging","volume":"23","author":"Kennedy","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2017.01.031_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.immuni.2016.08.017","article-title":"mTORC1 and mTORC2 Kinase signaling and glucose metabolism drive follicular helper T cell differentiation","volume":"45","author":"Zeng","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2017.01.031_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2017.01.031_bib6","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2017.01.031_bib7","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2017.01.031_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2017.01.031_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2017.01.031_bib10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2017.01.031_bib11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2017.01.031_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3816\/CBC.2003.n.018","article-title":"Mammalian target of rapamycin: a new molecular target for breast cancer","volume":"4","author":"Mita","year":"2003","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbrc.2017.01.031_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/cc.4.11.2159","article-title":"mTOR, a new therapeutic target in acute myeloid leukemia","volume":"4","author":"Recher","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2017.01.031_bib14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/leu.2010.170","article-title":"Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies","volume":"24","author":"Chapuis","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2017.01.031_bib15","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1128\/MCB.19.6.4302","article-title":"Translational homeostasis: eukaryotic translation initiation factor 4E control of 4E-binding protein 1 and p70 S6 kinase activities","volume":"19","author":"Khaleghpour","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2017.01.031_bib16","doi-asserted-by":"crossref","first-page":"11647","DOI":"10.1074\/jbc.274.17.11647","article-title":"Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of eIF4E and phosphorylation of ribosomal protein S6","volume":"274","author":"Kimball","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2017.01.031_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2049-3002-1-8","article-title":"Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase\/fructose 2,6-bisphosphatases in cancer metabolism","volume":"1","author":"Ros","year":"2013","journal-title":"Cancer Metab."},{"key":"10.1016\/j.bbrc.2017.01.031_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.yexmp.2009.01.003","article-title":"Regulation of glucose metabolism by 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatases in cancer","volume":"86","author":"Yalcin","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.bbrc.2017.01.031_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cmet.2013.11.008","article-title":"Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis","volume":"19","author":"Schoors","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2017.01.031_bib20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cell.2013.06.037","article-title":"Role of PFKFB3-driven glycolysis in vessel sprouting","volume":"154","author":"De Bock","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2017.01.031_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2015.07.052","article-title":"Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: modulation of PFKFB3 activation","volume":"464","author":"Ge","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2017.01.031_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3892\/or.2016.4884","article-title":"Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment","volume":"36","author":"Hu","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2017.01.031_bib23","doi-asserted-by":"crossref","first-page":"e0163768","DOI":"10.1371\/journal.pone.0163768","article-title":"PFK15, a small molecule inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer","volume":"11","author":"Zhu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2017.01.031_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1432-1033.1982.tb07039.x","article-title":"A\u00a0kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate","volume":"129","author":"Van Schaftingen","year":"1982","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbrc.2017.01.031_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10863-007-9081-2","article-title":"HIF-1 mediates the Warburg effect in clear cell renal carcinoma","volume":"39","author":"Semenza","year":"2007","journal-title":"J.\u00a0Bioenerg. Biomembr."},{"key":"10.1016\/j.bbrc.2017.01.031_bib26","doi-asserted-by":"crossref","first-page":"20534","DOI":"10.1074\/jbc.M611782200","article-title":"Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif","volume":"282","author":"Land","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2017.01.031_bib27","first-page":"5881","article-title":"High expression of inducible 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers","volume":"62","author":"Atsumi","year":"2002","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbrc.2017.01.031_bib28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","article-title":"Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy","volume":"30","author":"Cantelmo","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2017.01.031_bib29","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2017.01.031_bib30","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2010-10-265603","article-title":"Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns","volume":"117","author":"Gupta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2017.01.031_bib31","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17300402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17300402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T08:35:55Z","timestamp":1568709355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X17300402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0006291X17300402"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.01.031","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}